A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

NCT05738486 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1175

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders

Interventions

DRUG: Donanemab
DRUG: Placebo
DRUG: Dexamethasone

Sponsor

Eli Lilly and Company